Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.
Superinvestors holding CGEM, Q2 2026
No superinvestor reported holding CGEM in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of CGEM each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q4 2022
0 superinvestors holding at quarter end
- Sold out
- Baupost Group
Q3 2022
1 superinvestor holding at quarter end
- Reduced
- Baupost Group (−72.0%)
Q4 2021
1 superinvestor holding at quarter end
- Reduced
- Baupost Group (−16.3%)